Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 5/20 | 0.36 |
| ▸ | CDK1 | P06493 | 5/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083657 | 0.91 | FGFR1 (0.36) | CCNB2CDK1CCNB1CCNB3FGFR1 | |
| SCHEMBL5086430 | 0.84 | ADORA1 (0.38) | — | |
| SCHEMBL5082281 | 0.84 | FGFR1 (0.46) | FGFR1 | |
| SCHEMBL5086440 | 0.81 | DNPH1 (0.35) | FGFR1 | |
| SCHEMBL5086067 | 0.79 | FGFR1 (0.44) | FGFR1 | |
| SCHEMBL5086360 | 0.78 | FGFR1 (0.43) | FGFR1 | |
| SCHEMBL5086061 | 0.77 | FGFR1 (0.44) | FGFR1 | |
| SCHEMBL5082379 | 0.76 | FGFR1 (0.33) | FGFR1 | |
| SCHEMBL5083589 | 0.74 | ADORA2A (0.44) | FGFR1 | |
| SCHEMBL5086065 | 0.72 | ABL1 (0.38) | CCNB2CDK1CCNB1CCNB3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | CCNB2 428/4885CDK1 704/4885CCNB1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.